Exelixis Free Cash Flow vs Capital Expenditures Analysis
EXEL Stock | USD 33.82 0.34 1.02% |
Exelixis financial indicator trend analysis is much more than just examining Exelixis latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Exelixis is a good investment. Please check the relationship between Exelixis Free Cash Flow and its Capital Expenditures accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
Free Cash Flow vs Capital Expenditures
Free Cash Flow vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Exelixis Free Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have weak relationship.
The correlation between Exelixis' Free Cash Flow and Capital Expenditures is 0.37. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Exelixis, assuming nothing else is changed. The correlation between historical values of Exelixis' Free Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Exelixis are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Free Cash Flow i.e., Exelixis' Free Cash Flow and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | 0.37 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Capital Expenditures
Capital Expenditures are funds used by Exelixis to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Exelixis operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from Exelixis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Exelixis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.At this time, Exelixis' Selling General Administrative is quite stable compared to the past year. Tax Provision is expected to rise to about 32.5 M this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.24.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.4B | 1.6B | 1.8B | 1.8B | Total Revenue | 1.4B | 1.6B | 1.8B | 1.9B |
Exelixis fundamental ratios Correlations
Click cells to compare fundamentals
Exelixis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Exelixis fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.9B | 2.1B | 2.6B | 3.1B | 2.9B | 3.1B | |
Total Stockholder Equity | 1.7B | 1.9B | 2.2B | 2.5B | 2.3B | 2.4B | |
Retained Earnings | (559.4M) | (447.6M) | (216.5M) | (34.2M) | (173.4M) | (182.0M) | |
Common Stock Shares Outstanding | 315.0M | 318.0M | 322.4M | 324.6M | 321.5M | 178.5M | |
Liabilities And Stockholders Equity | 1.9B | 2.1B | 2.6B | 3.1B | 2.9B | 3.1B | |
Other Stockholder Equity | 2.2B | 2.3B | 2.4B | 2.5B | 2.4B | 1.4B | |
Short Long Term Debt Total | 50.7M | 49.1M | 51.3M | 190.2M | 189.9M | 179.6M | |
Other Current Liab | 21.7M | 179.2M | 313.3M | 284.2M | 360.5M | 378.5M | |
Total Current Liabilities | 142.7M | 204.7M | 337.6M | 324.4M | 394.3M | 414.0M | |
Property Plant And Equipment Net | 90.7M | 67.4M | 104.0M | 401.2M | 470.9M | 494.4M | |
Net Debt | (215.8M) | (270.1M) | (595.9M) | (311.0M) | (73.1M) | (69.4M) | |
Accounts Payable | 11.6M | 23.6M | 24.3M | 32.7M | 33.8M | 35.5M | |
Cash | 266.5M | 319.2M | 647.2M | 501.2M | 263.0M | 190.9M | |
Non Current Assets Total | 874.5M | 691.9M | 781.5M | 1.5B | 1.6B | 1.7B | |
Non Currrent Assets Other | 11.3M | 71.9M | 131.0M | 290.6M | 334.2M | 350.9M | |
Cash And Short Term Investments | 852.2M | 1.2B | 1.5B | 1.3B | 995.3M | 1.0B | |
Net Receivables | 119.1M | 160.9M | 282.7M | 214.8M | 237.4M | 249.3M | |
Short Term Investments | 585.7M | 887.3M | 819.9M | 807.3M | 732.3M | 768.9M | |
Non Current Liabilities Total | 57.0M | 53.6M | 68.0M | 258.7M | 284.2M | 213.1M | |
Other Current Assets | 27.0M | 57.0M | 57.5M | 62.2M | 67.9M | 71.3M | |
Total Liab | 199.7M | 258.2M | 405.6M | 583.1M | 678.4M | 370.3M | |
Total Current Assets | 1.0B | 1.4B | 1.8B | 1.6B | 1.3B | 1.4B | |
Accumulated Other Comprehensive Income | 3.1M | 4.5M | (758K) | (14.5M) | (3.8M) | (3.9M) | |
Short Term Debt | 2.7M | 3.0M | 8.7M | 17.7M | 25.7M | 50.4M | |
Common Stock | 305K | 312K | 319K | 324K | 303K | 287.9K | |
Other Liab | 8.9M | 4.5M | 16.8M | 68.5M | 78.8M | 83.4M | |
Other Assets | 185.3M | 187.1M | 197.5M | 286.9M | 329.9M | 346.4M | |
Common Stock Total Equity | 300K | 305K | 312K | 324K | 372.6K | 391.2K | |
Inventory | 12.9M | 21.0M | 27.5M | 33.3M | 17.3M | 9.5M | |
Property Plant And Equipment Gross | 90.7M | 67.4M | 144.9M | 462.1M | 551.2M | 578.8M | |
Property Plant Equipment | 48.9M | 67.4M | 149.2M | 110.6M | 127.2M | 133.6M | |
Current Deferred Revenue | 106.7M | 1.8M | 8.7M | 6.6M | 5.4M | 5.1M | |
Net Tangible Assets | 1.6B | 1.8B | 2.0B | 2.4B | 2.8B | 2.9B | |
Retained Earnings Total Equity | (880.4M) | (559.4M) | (447.6M) | (34.2M) | (39.4M) | (41.3M) | |
Capital Surpluse | 2.2B | 2.2B | 2.3B | 2.5B | 2.9B | 2.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.